"We are delighted that Sue's knowledge of and commitment to the life sciences industry has been recognized in this manner, and expect her to make a great contribution to Governor Patrick's initiative," said Steven Fosburg, President of ABS. "Although we are sorry to lose her as a colleague, as members of the Massachusetts life sciences community we look forward to seeing the benefits of her efforts for many years to come. Here at ABS, we anticipate a seamless transition as Nandini takes over sole leadership of our commercial strategy practice. We expect great things from her, as the group is poised for significant growth in the coming year and Nandini is the right candidate to lead that effort."
Ms. Hadker holds a Masters in Economics from Boston University and her work has been published in numerous peer-reviewed, scientific healthcare journals including The Journal of Occupational and Environmental Medicine and Haemophelia. She has also been a featured speaker at many professional conferences, especially in the area of new product planning and pharmaceutical pricing.
The ABS team has provided integrated strategic, research, and
communications services to the pharmaceutical, biotechnology, medical
device, and diagnostics industries for more than 20 years. The company
specializes in demonstrating the value, safety, and efficacy of health
technologies through prospective studies such as registries and clinical
trials as well as through analyses of retrospective data. ABS teams of
senior, seasoned staff help sponsors develop their research agendas,
successfully conduct their research programs, communicate the results in
peer-reviewed journals, and, where appropriate, appear before regulatory
authorities. Primary service offerings include registries and othe
|SOURCE Abt Bio-Pharma Solutions, Inc.|
Copyright©2008 PR Newswire.
All rights reserved